Look behind the lecture: patient-reported outcomes in cancer trials

Written by The Evidence Base

In this interview, Jessica Roydhouse, of the US FDA, discusses her presentation from the 2019 annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR; 18–22 May, New Orleans, LA, USA) on the impact of patient-reported outcomes on the design and analysis of cancer clinical trials. Please can you introduce yourself and explain your role at FDA? I am an Oak Ridge Institute for Science and Education (ORISE; TN, USA) Fellow at the US FDA (MD, USA) in the Office of Hematology and Oncology Products. I conduct research on patient-reported outcomes (PROs) in clinical cancer trials, focusing on...

To view this content, please register now for access

It's completely free